Navigation Links
Horizons AMI trial data to be presented at TCT 2007
Date:10/15/2007

WASHINGTON, DC OCTOBER 15, 2007 -- The Cardiovascular Research Foundation (CRF) will release results of its landmark research study, HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) at the nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. The study is designed to examine the safety and effectiveness of stents and anticoagulants in heart attack patients undergoing angioplasty.

The HORIZONS AMI trial data will be presented at a press conference on Wednesday, October 24 at 8:40 am. The results will be presented as a late breaking trial on Wednesday, October 24 at 10:50 am.

This is a landmark trial, which will help set guidelines for drug and stent therapy during primary angioplasty in patients with heart attacks for many years to come, said Gregg W. Stone, MD, Chairman of the Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center.

While previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the highest risk form of heart attack (ST-elevation myocardial infarction).

Usually, angioplasty is associated with an excess of bleeding in heart attack patients, Dr. Stone said. However, using the anticoagulant bivalirudin with angioplasty in patients with stable coronary artery disease instead of heparin and glycoprotein IIb/IIIa inhibitors reduces bleeding, which has been associated with greater long-term survival. In the HORIZONS AMI trial, we have sought to determine whether using bivalirudin in patients with a heart attack, who undergo angioplasty, provides the same benefit.

This study should determine if bivalirudin use is as efficacious as the standard anticoagulant therap
'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Teens who are sensitive ... likely to develop emotional symptoms such as anxiety and ... as these that may exacerbate issues teens experience after ... and in making decisions about when to return to ... these athletes," study authors Lisa Koehl and Dong Han, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Men who have a vasectomy ... a new study suggests. But the risk is ... involved with the study said more research is needed ... For the study, Harvard researchers analyzed data from ... 24 years, starting in 1986. During that time, 6,023 ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... Emergency Medical Service (EMS) responders felt better prepared to ... tactical training according to a new study in the ... the first study to specifically examine the EMS provider ... a shooter has not yet been neutralized or working ... such as the Columbine High School shooting, the Virginia ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Active shooter training increases comfort level of emergency responders 2
... associated with Alzheimer,s and mad cow disease, turns out ... paper published in Nature Chemical Biology , Frederic ... Universiteit Brussel describe that certain mutations of p53, an ... a way that the proteins start to aggregate. This ...
... 29 (HealthDay News) -- Dangerous methicillin-resistant staphylococcus aureus, or MRSA, ... this seasonal increase is more common in children than adults, ... analysis of MRSA cases that occurred at Rhode Island Hospital, ... children,s infections were higher in the third and fourth quarters ...
... application provided by the UK Resuscitation Council performed significantly ... did not, according to a study in the April ... approximately 30,000 people in the UK have an unexpected ... resuscitation research, survival rates for adults suffering a cardiac ...
... that liver transplant recipients who quit smoking have a ... keep smoking. In fact, SRMs were identified in 13.5% ... higher risk of malignancy in this study. Full findings ... Transplantation , a journal of the American Association for ...
... News) -- Death rates among teens and young adults aged 15 ... 4 years in many countries, says a new study that ... of researchers that analyzed the causes and patterns of death among ... 2004 also found that death rates among young males aged 15 ...
... Severely obese men and women who have bariatric surgery may ... much of their pre-surgery risk for experiencing disabling migraines, researchers ... a small study of obese patients with a history of ... roughly 66 pounds by the half-year point following either laparoscopic ...
Cached Medicine News:Health News:Cancer is a p53 protein aggregation disease 2Health News:MRSA Infections May Vary by Season 2Health News:Free phone app helped doctors perform better in simulated cardiac emergency 2Health News:Smoking in combination with immunosuppression poses greater risk for transplant-related carcinoma 2Health News:Death Rates of Children, Young Adults Show Reversal 2Health News:Weight-Loss Surgery May Cut Migraine Pain in Obese Patients 2Health News:Weight-Loss Surgery May Cut Migraine Pain in Obese Patients 3
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... device company, announced that,the two-year data from ... Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will be presented today ... study examined the safety and efficacy of ...
... 26, 2007 /PRNewswire-FirstCall/ --,Australian drug development company ... randomised Phase II clinical,trial in patients with ... compared to irinotecan which is,considered to be ... colorectal,cancer. This announcement is being made at ...
Cached Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7
... CC 527 is an assayed quality control material ... electrolyte, and CO-Oximeter instrumentation. It is for specific ... and hemoglobin fractions (280, 288, and 270) and ... 527 may also be used on the IRMA ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
For the qualitative detection of igG antibodies specific to Helicobacter pylori in human serum, plasma and whole blood specimens...
Medicine Products: